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Abstract 
Reduced insulin sensitivity in a pre-diabetic state might increase the susceptibility to 
acute mountain sickness (AMS). Dexamethasone’s diabetogenic side effects could 
therefore play a role in the medical treatment of AMS.  
To examine whether reduced insulin sensitivity is predictive of AMS and how this 
parameter is affected by dexamethasone at high altitude, we analyzed endocrine and 
metabolic parameters obtained from healthy mountaineers who spent 5 days at an 
altitude of 4559m. 
Blood samples were taken in Zurich (ZH;490m) and 2 and 4 days after a fast ascent 
to the Capanna Regina Margherita (MG2, MG4;4559m). 14 of 25 participants (15/10 
m/f) developed AMS and were treated with dexamethasone starting in the evening of 
Day 2 until descent. Before and after ingestion of an 1800kJ solid meal, plasma was 
analyzed for several hormones including erythropoietin (EPO) and cholecystokinin 
(CCK). Insulin sensitivity (HOMA-S) and beta cell activity were calculated from 
measured fasting insulin and glucose blood levels. 
HOMA-S (p<0.01) and EPO levels (p<0.05) were lower at baseline in Zurich in the 
dexamethasone group i.e. before any treatment and exposure to hypoxia. CCK was 
lower (p<0.01) and glucose and insulin were higher on MG4 in the dexamethasone 
group compared to the untreated group. 
 
The main finding in our study was that individuals with low baseline insulin sensitivity 
and low baseline EPO levels were more susceptible to AMS. Reduced CCK 
secretion may contribute to the beneficial effect of dexamethasone on high altitude 
anorexia. However, reduced insulin sensitivity may question dexamethasone’s 
widespread use to prevent/treat AMS. 
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Introduction 
 
More and more people living at or near sea level spend their spare time with activities 
such as hiking, skiing or climbing at higher altitude (> 2500m above sea level). The 
numbers of patients with metabolic syndrome, decreased insulin sensitivity or 
manifest diabetes increase worldwide and antidiabetic treatments have improved in 
recent years. As a result more patients with metabolic problems expose themselves 
to hypoxic conditions and may therefore want to benefit from prophylactic treatments, 
including dexamethasone. Dexamethasone is often used by mountaineers to prevent 
or treat acute mountain sickness (AMS) (14, 21, 27). 
AMS has an incidence of 15-80% depending on individual susceptibility, 
acclimatization, speed of ascent and maximum height reached above 2500m (13, 20, 
32, 33). Most common symptoms of AMS are headache, insomnia, fatigue, 
dizziness, breathlessness, anorexia and nausea (13, 19, 46, 53).  
The underlying molecular mechanisms for dexamethasone-mediated improvement of 
mountaineers suffering from AMS are complex and only partly understood. This is 
due to the fact that the primary cause of AMS is still not well known. Because 
hypoxia-induced systemic inflammation may play a role in the development of AMS 
(15, 22, 23), the anti-inflammatory and immunosuppressant action of dexamethasone 
could at least partly be responsible for dexamethasone’s beneficial effects in AMS. 
Further, dexamethasone may modulate the release and action of gastrointestinal 
hormones that control food intake. Cholecystokinin (CCK), that has been shown to be 
increased in plasma at high altitude, may play a role in the development of AMS-
caused anorexia (4). CCK is also known to be decreased by dexamethasone in cell 
cultures and in rats in-vivo (41).  
Dexamethasone, however, has a wide range of undesired side effects. In addition to 
its immunosuppressant impact that potentially increases the risk of infections and 
impaired wound healing, glucocorticoids have catabolic and diabetogenic effects on 
fat and carbohydrate metabolism (25, 48, 50). Unfortunately for diabetics the risk of 
side effects of dexamethasone treatment is even higher than for healthy subjects 
because high altitude hypoxia itself may lead to changes in glucose homeostasis (17, 
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24). This may result in changed insulin requirements and, eventually, in a 
deterioration of their metabolic disorders.  
Therefore, as a primary endpoint we investigated potential metabolic differences in 
patients with AMS in particular concerning insulin sensitivity, metabolites, glucose 
metabolism and gastrointestinal hormones. All these data were analyzed 
retrospectively depending on whether individuals required dexamethasone or not. 
Second, we also attempted to estimate the effect of the dexamethasone treatment in 
a subgroup of participants.  
 
Methods 
Subjects 
Twenty-five healthy and experienced mountaineers (15 male; 22-60 years) were 
recruited by adverts in mountain journals. As we were interested in AMS and 
therefore avoided acclimatization, volunteers were not allowed to stay more than 3 
nights above 2500m one month prior to the fast ascent. Exclusion criteria were 
chronic diseases, regular medication, history of transplantation, clinically significant 
heart valve diseases and congenital heart or lung disease. Most volunteers had a 
body mass index (BMI) between 18 and 25 kg/m2, but two persons with a BMI slightly 
above 25 and one with a BMI of 31 were also included. Participants had to show 
normal eating behavior and were not allowed to require special diets. Eight subjects 
were known to have experienced high altitude pulmonary edema (HAPE) in past 
ascents to altitude. The Ethics Committee of the Canton of Zurich approved the study 
(EK-1677) that conformed to the declaration of Helsinki. 
 
Study procedure and power calculation 
We performed a power calculation to assess the sample size for the endpoint 
detection of a significant effect of dexamethasone on postprandial glucose 
concentrations. These calculations were based on a recent study by Abdelmannan et 
al. (1). Those authors tested different doses of dexamethasone on postprandial 
glucose concentrations in healthy volunteers after a 75g oral glucose tolerance test 
(OGTT) and measured an increase of blood glucose concentrations from 127 ± 7.1 
mg/dL to 176 ± 19 mg/dL after a single dose of 8mg dexamethasone given 24h 
before the following OGTT. The carbohydrate amount given in the present study and 
the single dose treatment with dexamethasone were comparable to the experimental 
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settings in the previous study (carbohydrate content of the muffin 52.91 g). Based on 
these data we calculated a sample size of only 4 volunteers and decided that a 
sample of 25 healthy volunteers would be high enough to detect a significant 
difference for our endpoint (effect size dz = 2.9467321,  Į error probability = 0.05, 
power (1-ȕ error probability) = 0.95 ; noncentrality parameter į = 5.8934642, critical t 
= 3.1824463, df = 3, analysis done by G*Power Version 3.1.3). 
Subjects underwent baseline physical examinations to ensure they met the inclusion 
criteria. First blood samplings were done in Zurich (ZH, 490 m above sea level, pO2 
140-150 mmHg) to generate baseline values. Groups of 4-5 subjects each were then 
exposed to hypoxia using a fixed schedule; all experiments were performed in the 
summer of 2009 over a period of 5 weeks. Each group started at Day 0 in Alagna 
Valsesia (Italy, 1205 m), was transported by cable car to 3000 m, then walked to the 
Capanna Gnifetti at 3600 m (pO2 94-103 mmHg) in the Monte Rosa region and 
stayed there overnight. On Day 1 the groups ascended to arrive in the late morning 
at the Capanna Regina Margherita (4559 m, pO2 81-91 mmHg), where all tests at 
high altitude were done (Fig. 1). 
 
AMS assessment and medication 
Occurrence of AMS was assessed using the Lake Louise Score (LLS>5) and through 
medical examination by experienced physicians. This study was not designed to 
assess the effects of dexamethasone on high altitude physiology in a randomized 
double blind placebo controlled fashion. Therefore for safety reasons only subjects 
with high HAPE susceptibility, a LLS greater 5 in the morning or evening of MG2 or 
necessity identified by medical examination were treated with 2 x 8 mg/day 
dexamethasone (9-fluor-16a-methylprednisolone, Dexamethasone Galepharm, 4 mg, 
Galepharm AG, 8700 Kuesnacht, Switzerland) starting on the evening of MG2, i.e., 
after the last blood sample had been taken on that day. One person had to be treated 
with dexamethasone already earlier on Day 2 so that this subject was excluded from 
the analysis. Due to the occurrence of AMS, 14 subjects had to be treated with 
dexamethasone (DEX) and 11 served as untreated controls (CON). 
 
Study design and sample processing 
Blood gas analysis was done in blood taken from the arteria radialis using an ABL 5 
blood gas analyzer (Radiometer, Copenhagen). Blood samples were taken at ground 
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level in Zurich (ZH) and on Days 2 and 4 (MG2 and MG4) at the Capanna Regina 
Margherita. On the morning of each test day, a venous catheter was placed in the 
forearm to allow for blood sampling. Blood sampling was performed in the morning 
before an ad libitum breakfast at 7am (fasted hormone levels, Figs 2 and 3), just 
before and 30, 60, 90, 120, 180, 240 min after a test meal of two muffins at 01:00 pm 
(1.76 g dietary fiber, 12.52 g protein, 18.06 g fat, 52.91 g carbohydrates, 1800 kJ), 
and between an additional muffin preload and ad libitum dinner at 07:00 pm of each 
test day. For dinner, subjects were offered pasta, bolognese sauce, grated parmesan 
cheese and two sorts of biscuits. They were free to choose what and how much of 
the different foods they wanted to eat; all food consumed was weighed on a kitchen 
scale to the nearest gram, and energy intake was calculated. EDTA-plasma samples 
were kept frozen in liquid nitrogen or stored in -80°C for later analysis.  
 
Plasma analysis  
Inflammation markers 
Cortisol was determined by electrochemiluminescence (Elecsys® Cortisol, Roche, 
Switzerland). Interleukin-6 (IL-6) and tumor necrosis factor-Į (TNF-Į) were measured 
using the Milliplex® MAP Human Cytokine/Chemokine Assay (Millipore). 
Erythropoietin (EPO) was determined with the Human Erythropoietin Immunoassay 
(Quantikine, IVD, R&D Systems, Minneapolis, USA). 
Gastrointestinal hormones 
The Milliplex® MAP Kit Human Endocrine (Millipore, Billerica, MA, USA) was used 
for amylin. Cholecystokinin (CCK-8; active) was measured using Radioimmunoassay 
Kits (Eurodiagnostica, Burgdorf, Switzerland) by Prof. Christoph Beglinger, University 
Hospital Basel, Switzerland.  
Glucose homeostasis 
Glucose was measured by an enzymatic UV-Test with a Cobas Mira analyzer 
(Roche, Switzerland) and insulin by an ultra-sensitive Human Insulin RIA Kit 
(Millipore). 
 
Calculations 
Homeostasis model assessment (insulin sensitivity: HOMA S=(glucose*insulin)/22.5); 
beta cell activity: HOMA B=(20*insulin)/(glucose-3.5)), fasting glucose to insulin ratio 
(G:I) and quantitative insulin sensitivity check index 
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(QUICKI=1/((LOG(insulin))+(LOG(glucose)) were calculated by using the measured 
values of fasting insulin (mU/l) and fasting glucose (mmol/l) (18, 36). 
 
Statistics  
Statistical analysis was performed with Graphpad Software (San Diego California, 
USA). Power Analysis was done using G*Power Version 3.1.3. Some data were 
skewed and had different variances. To compare two groups on one test day 
significance was determined by Students t-test with Welch’s correction. For 
comparison of different test days within groups the Wilcoxon matched-pairs signed 
rank test was used. Two-way ANOVA with Bonferroni post-hoc tests were used to 
compare hormone and metabolite levels over the course of the day. Area under the 
curve (AUC) was calculated for various time periods for hormones with the value of 
the plasma sample “before muffin” set as baseline. AUC therefore indicates the 
changes in plasma levels relative to individual baselines. Odds ratios with confidence 
interval and Fisher’s exact test were calculated to define the risk to develop AMS in 
subjects with baseline EPO plasma levels l< 6 mU/ml and a HOMA S level  2 at 
baseline in ZH. In the case of HOMA S one value equaled zero; 0.5 was therefore 
added to all values to make the calculation of the odds ratio possible. Significance 
was assumed with a p-value   0.05. 
 
 Results 
Baseline characteristics  
No significant differences were found between the dexamethasone-treated (DEX) 
and untreated groups (CON) in BMI, body weight, age, gender and in systolic, 
diastolic blood pressure and peripheral oxygen saturation on any test day (Table 1). 
Eight out of the 25 subjects were known to have suffered from HAPE before.  
 
Hypoxia and clinical high altitude illness 
Both groups decreased their arterial PO2 on MG2 and MG4 (mean of 12.4 ± 1.2 kPa 
in ZH to 5.2 ± 0.6 kPa on MG2 and 5.9 ± 0.6 on MG4; p < 0.001); mean peripheral 
oxygen saturation also decreased compared to baseline levels (97.3 ± 1.4% in ZH to 
75.3 ± 8.5% at MG2 and 81.5 ± 7.3% at MG4; p < 0.001).  
Lake Louise Score (LLS) was increased in both groups on MG2 compared to ZH (p < 
0.01) and tended to be higher in MG2DEX compared to MG2CON (p = 0.07). On 
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MG4 LLS decreased but the effect was only significant in the dexamethasone-treated 
group (p < 0.05 for MG2DEX vs. MG4DEX; p = 0.16 for MG2CON vs. MG4CON). In 
both groups LLS remained higher on MG4 compared to ZH (p < 0.05) (Fig. 2A). 
As expected, plasma EPO levels were increased in all subjects on MG2; EPO then 
decreased from MG2 to MG4, but remained higher on MG4 compared to ZH 
(MG2CON and MG4CON to ZHCON p < 0.01; MG2DEX and MG4DEX to ZHDEX p 
< 0.001). EPO levels decreased from MG2 to MG4 in both groups, but were lower in 
MG4DEX than in MG4CON (p < 0.05) (Table 1). Unexpectedly, EPO levels were 
lower in the dexamethasone-treated group than in the untreated control group at 
baseline in ZH (p < 0.05) i.e. before any dexamethasone treatment (Table 1). The 
odds ratio for the risk of suffering from AMS for subjects with EPO levels < 6 mU/ml 
at baseline in ZH was 10.5 with a confidence interval (CI) of 1.36 - 81.09 and a p-
value of 0.03 in the Fisher’s exact test. 
 
Blood Metabolites and insulin 
Plasma glucose concentration was higher in MG4DEX than in MG4CON at most time 
points of the day (p < 0.001 morning, before muffin, 60, 90 min after muffin; p < 0.01 
30 min; p < 0.05 120, 180, 240 min) (Fig. 3A). Other metabolites including 
betahydroxybutyrate, triglycerides, free fatty acids and lactate did not differ 
significantly across groups (data not shown). 
Retrospective analysis of baseline data in ZH indicated that plasma insulin was 
higher in DEX compared to CON at 60 min (p < 0.01). Comparison of the study days 
within groups showed no significant difference at any time point in CON, but insulin 
was higher in DEX on MG2 compared to ZH 30 and 60 min postprandially (pp) (Fig. 
3B, p30 < 0.001, p60 < 0.01). Two-way ANOVA revealed an overall effect of 
dexamethasone and altitude in MG4DEX compared to ZHDEX (p < 0.001), but did 
not detect a significant difference between time points. MG4DEX had higher levels at 
30 and 60 min than MG2DEX (p < 0.001). Insulin levels were higher in MG4DEX 
than in MG4CON after the test meal and just before dinner (p < 0.001 60, 90 min pp; 
p < 0.01 30, 120 min pp; p < 0.05, 180 min pp, before ad lib) (Fig. 3B). Fig. 4A 
represents fasting insulin levels taken before breakfast and demonstrates higher 
levels in ZHDEX compared to ZHCON (p < 0.01) and in MG4DEX compared to 
MG4CON (p < 0.001).  
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The AUC of insulin was smaller in MG2DEX than in ZHDEX at the time points 30, 60 
and 90 min (p30 < 0.05, p60 < 0.01, p90 < 0.05), and greater in MG4DEX than in 
ZHDEX at the time points 120, 180 and 240 min (p120 < 0.05, p180 < 0.01, p240 < 
0.001). At 180 min MG4CON was greater than ZHCON (p < 0.05). At the time points 
180 and 240 min the AUC of insulin was greater in MG4DEX than in MG4CON (p < 
0.05)(data not shown). 
 
Assessment of insulin sensitivity 
Calculation of homeostasis model assessment (HOMA) levels indicated that insulin 
sensitivity (HOMA S) was lower in MG4DEX than in MG4CON (p < 0.001). While this 
effect was expected considering the known effect of dexamethasone on glucose 
metabolism, it is remarkable that insulin sensitivity also was lower in ZHDEX 
compared to ZHCON (p < 0.01) i.e. already at baseline before any treatment. The 
odds ratio for the risk of developing AMS for subjects with HOMA S baseline levels in 
ZH  2 was calculated as 22.5 with a confidence interval of 1.1 - 480.3 and p = 0.014 
in the Fisher’s exact test. HOMA S increased in MG2CON compared to ZH (p < 0.05) 
and in MG4DEX compared to ZH (p < 0.01) (Fig. 4B). Beta cell activity (HOMA B) 
remained unchanged. Fasting glucose to insulin ratio (Fig. 4C) was lower in ZHDEX 
and MG2CON compared to ZHCON (p < 0.05, p < 0.01) and also lower in MG4DEX 
than in MG4CON (p < 0.05). QUICKI values were significantly lower in ZHDEX and 
MG2CON than in ZHCON (p < 0.05) and lower in MG4DEX compared to ZHDEX and 
MG4CON (p < 0.01, p < 0.001) (Fig. 4D). 
 
Inflammation markers and cortisol 
Endogenous cortisol was measured as an internal treatment control standard in all 
individuals before and after medication with dexamethasone (Fig. 2B). As expected, 
endogenous cortisol was markedly lower after treatment (MG4DEX vs. MG4CON p < 
0.001). Retrospective analysis indicated, however, that endogenous cortisol did not 
differ between groups in ZH or at MG2; in other words, endogenous cortisol was only 
suppressed in dexamethasone-treated participants. Based on similar cortisol levels 
on MG2 and ZH in both groups, the ascent on Days 0 and 1 had no influence on 
MG2. 
Plasma IL-6 concentrations increased in both groups on MG2 compared to ZH (CON 
p < 0.05, DEX p < 0.01). IL-6 tended to be lower on MG4 than on MG2, but this 
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difference was only significant in the control group (p < 0.05) and not in the 
dexamethasone-treated group (MG2DEX vs. MG4DEX, p = 0.07) (Fig. 2C). 
Plasma TNF-Į levels were lower in MG4DEX than in MG4CON (p < 0.05) (Fig. 2D). 
CCK, Amylin 
Plasma levels of amylin did not differ at individual time points across groups, i.e. 
there was no effect of either hypoxia or dexamethasone treatment. Amylin and CCK 
increased as expected after the muffin test meal in both groups and on all days. (Fig 
3 C) 
Interestingly, CCK levels were lower in MG4DEX compared to MG4CON 30 min (p < 
0.05) and 60 min (p < 0.01) after the test meal (Fig. 3C). The AUC of CCK was also 
smaller in DEX compared to CON on MG2 30, 60 and 90 min after the test meal (p < 
0.05). The AUC was greater in MG4CON compared to ZH 30, 60 and 90 min 
postprandially (p30 < 0.01, p60 < 0.01, p90 < 0.05); compared to MG4DEX, it remained 
higher over all time points after the muffin test meal (before breakfast p < 0.05, all 
other time points p < 0.01) (data not shown). 
Amylin had a greater AUC at MG2 in CON 30 and 60 min after the muffin test meal 
(p < 0.05). Ninety to 240 min after the muffin the AUC of amylin was greater in CON 
at MG2 than on ZH (p < 0.001) (data not shown). 
Similarly, we also measured PYY and gastrin over the course of the study but did not 
detect any differences among groups (data not shown). 
 
Caloric intake ad libitum dinner 
Energy intake (kcal) during the ad libitum dinner was lower in DEX on all three days 
(p < 0.05) and was decreased in both groups on MG2 compared to ZH (ZHCON vs. 
MG2CON p < 0.01; ZHDEX vs. MG2DEX p < 0.05). Energy intake returned to nearly 
baseline levels on MG4 (MG2CON vs. MG4CON p < 0.05; MG2DEX vs. MG4DEX p 
< 0.01) (Fig. 5). 
Taken together, our findings indicate that baseline insulin sensitivity and baseline 
EPO levels were lower in individuals at risk of AMS; these individuals required 
dexamethasone treatment in the evening of MG2 because of the development of 
AMS. 
 
Discussion 
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The exact causes and mechanisms of AMS remain unknown. Here we intended 
primarily to study specifically the effects of AMS on pre- and postprandial metabolism 
of a caloric solid meal. Second we were interested in side effects of dexamethasone 
treatment on metabolism in AMS prone patients when exposed to high altitude-
induced hypoxia. Our results did not only confirm the expected effect of 
dexamethasone on glucose homeostasis but also revealed differences between the 
two groups in plasma EPO levels and insulin sensitivity already at baseline in Zurich, 
i.e., at low altitude and before treatment with dexamethasone. 
The clinical appearance of AMS, as reflected by the Lake Louise Score (LLS), was 
induced by the fast ascent to high altitude with an increase on MG2 and a decrease 
due to acclimatization on MG4 in both groups as expected (20, 26). The prevalence 
of 57% of AMS in our subjects lies within the upper range of the data reported by 
other groups that found a prevalence of 30-60% at altitudes between 4243m and 
5671m (5, 20, 32, 54). This may be due to the fast ascent in our study and to the 
study design that included eight subjects with known HAPE susceptibility. The 
decrease in LLS on MG4 after dexamethasone clearly shows the effective 
improvement in well-being of the subjects who suffered from AMS but were 
successfully treated with dexamethasone, as it has been reported previously (49).  
Endogenous cortisol was measured and analyzed to proof dexamethasone’s 
efficacy. The suppressive effect of dexamethasone on endogenous cortisol 
production was as expected (9, 38), i.e., the dexamethasone-treated group showed a 
marked decrease in the plasma levels of endogenous cortisol at MG4. Hence, the 
medication of the individuals suffering from AMS was considered successful. 
 
Cytokines 
Consistent with other studies, the plasma concentration of IL-6 - but not of the other 
cytokines - increased due to exposure to high altitude hypoxia. (15, 23). Plasma IL-6 
and TNF-Į decreased in the dexamethasone-treated group on MG4, an expected 
observation due to the anti-inflammatory effect of dexamethasone. 
 
EPO 
Erythropoietin expression is up-regulated by hypoxia (8). As expected, plasma EPO 
levels therefore increased on MG2 after the fast ascent. Endogenous EPO has a 
relatively short plasma half-life of 6-9 hours (8). Our results therefore indicate that the 
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EPO production was still higher on MG4 compared to ZH but lower compared to 
MG2. The significantly lower EPO plasma level in the dexamethasone-treated group 
on MG4 can be explained by the effect of dexamethasone on gene transcription of 
cytokines via the glucocorticoid receptor (3, 39, 47). Hypoxia inducible factor (HIF) 
enhances EPO gene transcription in response to hypoxia (51), and Gaber et al. 
showed in cultured cells that dexamethasone suppresses the expression of HIF (12). 
Unfortunately this effect interferes with the acclimatization to high altitude hypoxia 
and, hence, contributes to the necessity to descend in case of AMS despite 
medication with dexamethasone. Further possible influences on plasma EPO levels 
such as EPO clearance from blood, have not well been investigated yet. 
In apparent contrast to our study Pavlicek et al. reported no difference in baseline 
levels but a significantly higher EPO plasma level in HAPE susceptible subjects at 
high altitude (40). Of note, one of the inclusion criteria for our study was, that the 
subjects were not allowed to spend more than 3 nights at 2500 m or higher one 
month prior to the study, but we did not completely exclude activities at altitude. 
Altitude activities prior to the study and a better general state of physical fitness may 
have lead to the slightly but significantly higher EPO levels in ZH in the group that did 
not suffer from AMS (11). However, another study (45), which also included some of 
the subjects who participated in our experiments, found that VO2max as parameter for 
aerobic capacity did not differ between HAPE susceptible and control subjects 
Hence, our results do not clearly indicate, whether there is a direct connection 
between plasma EPO levels at near sea level and susceptibility to AMS. 
 
Glucose metabolism 
Glucose metabolism was affected by dexamethasone on MG4 as expected. 
Dexamethasone has been shown to increase glucose levels in other studies [e.g. 
(35)]. We could not confirm, however, the increased glucose levels due to hypoxia or 
AMS itself reported by Larsen et al. (24). Glucocorticoids affect glucose metabolism 
in several ways, they impair insulin dependent glucose uptake in the periphery and 
enhance gluconeogenesis in the liver (42, 43). 
Our data show that glucose and insulin levels increased and, hence, insulin 
sensitivity decreased after dexamethasone treatment on MG4, which was expected 
(1). No significant changes due to hypoxia could be seen on MG2. Surprisingly, 
however, we found a lower insulin sensitivity in Zurich at baseline – which has to be 
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clearly differentiated from diagnosed diabetes – in the subjects that later suffered 
from AMS and had to be treated with dexamethasone. This may be an indication of 
higher susceptibility of those individuals for AMS. We did not evaluate the subjects 
with respect to any hereditary predisposition for diabetes. Of note Henriksen et al 
showed that dexamethasone differentially alters muscle glucose metabolism of 
normoglycemic relatives of type 2 diabetic patients (17). The lower plasma EPO 
levels in the dexamethasone-treated group already at baseline may also contribute to 
reduced insulin sensitivity because it has been shown that EPO improves glucose 
tolerance in mice by changing muscle metabolism (10, 22, 32), and because EPO 
treatment of anemia in uremic patients improved insulin resistance and alleviated 
hyperinsulinemia (34).  
Insulin sensitivity is impaired in patients with metabolic syndrome, but other 
symptoms such as increased blood pressure or higher BMI did not appear to be 
prevalent in our subjects (44). Although they did not yet show any obvious symptoms 
of diabetes or even overt changes in blood glucose levels, people predisposed for 
diabetes may have more difficulties to handle those side effects of dexamethasone 
because they aggravate their insulin resistance, that might have been undetected 
before. Therefore we analyzed insulin sensitivity by different models using fasting 
insulin and glucose levels, but all yielded consistent findings. We did not perform 
hyperinsulinemic-euglycemic clamps or oral glucose tolerance tests in our study. 
Another possible indicator for assessing the blood glucose concentration over a 
longer period of time is glycated hemoglobin (HbA1c) (6, 16). Nevertheless, we are 
convinced that the calculations of HOMA, QUICKI, glucose to insulin ratio combined 
with the values of fasting insulin are helpful and reliable indices to assess insulin 
resistance (18, 36, 37).  
 
Hormones 
Plasma CCK levels of MG4CON tended to be higher at one time point (30 min 
postprandially) compared to ZH and MG2, but this difference did not reach statistical 
significance. We could therefore not confirm the increase in resting plasma CCK that 
Bailey et al. found at high altitude (4). The AUC revealed a significantly higher 
increase of CCK in MG4CON compared to ZH and MG4DEX, which may indicate 
that hypoxia could still have had some influence. This finding, combined with the 
significantly lower levels in MG4DEX compared to MG4CON, confirms an effect of 
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dexamethasone on CCK levels similar to what had already been reported by 
Gatineau et al. in both, cell culture and rat experiments (41). Therefore, the decrease 
in CCK may play a role in the improvement of AMS-associated anorexia after 
dexamethasone treatment. 
Although we found no significant difference at single time points in amylin plasma 
levels that would implicate an effect of hypoxia or dexamethasone, we observed 
significant differences in the postprandial AUC. The AUC revealed that amylin 
increased more in MG2CON compared to MG2DEX at the time points 30 and 60 min 
and compared to ZHCON for the time points 90, 120, 180 and 240 min. Therefore the 
food intake induced amylin response seems to be different in subjects at high altitude 
compared to sea level and compared to subjects suffering from AMS. This needs to 
be further investigated but at least our data suggest that dexamethasone has no 
effect on amylin plasma levels.  
 
Caloric intake 
The overall effect of hypoxia on eating, in particular the significant decrease of caloric 
intake during the ad libitum dinner in both groups on MG2 confirms the results of 
earlier studies (28, 52). The increase in caloric intake back to nearly baseline (ZH) 
levels in both groups on MG4 was probably due to acclimatization and the 
dexamethasone treatment in the DEX group (7). Subjects at risk for AMS (DEX) ate 
less than the control group on all three test days. As we did not measure hormone 
levels and metabolites during and after the ad libitum dinner, potential mechanisms 
need to be tested in future studies. For detailed analysis of caloric intake in our test 
subjects please see Aeberli et al. (2). 
Finally, some limitations of our study need to be mentioned. First, medication was not 
blinded and we had no placebo control group included due to the primary endpoint of 
this large-scale study. In other words, any individual who required dexamethasone 
treatment due to medical condition and development of AMS received the drug. The 
other individuals remained untreated. Nonetheless, we believe that the main 
conclusion of our study, i.e., that low insulin sensitivity may predispose for AMS when 
exposed to hypoxia, is interesting and remains valid. As the data were analyzed 
retrospectively, we did not carry out oral glucose tolerance tests or hyperinsulinemic-
euglycemic clamps that would have allowed for stronger conclusions concerning the 
state of glucose metabolism. Second, due to some technical difficulties in blood 
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sampling under field conditions and analysis, the group size (n) for some parameters 
is rather small.  
To summarize, our results provide evidence indicating that dexamethasone in the 
treatment of AMS has not only positive effects on inflammation and altitude anorexia, 
but also carries the risk of a potentially dangerous influence on glucose metabolism, 
in particular as our data indicate that people with decreased insulin sensitivity may be 
more susceptible to AMS. Finally, this study emphasizes a clear need for further 
investigation and reminds the reader that dexamethasone is a potent drug but, due to 
the numerous possible side effects, also potentially dangerous, when taken at high 
altitude. 
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Fig. 1  
Scheme of study travel itinerary  
 
Fig. 2 Inflammation and clinical AMS 
Effects of hypoxia and dexamethasone on Lake Louise score (LLS) (A; n CON=11, 
DEX=14) and on plasma concentrations of cortisol (B; n CON=9, DEX=12), 
interleukin-6 (IL-6) (C; n CON=9, DEX=11), tumor necrosis factor alpha (TNFĮ) (D; n 
CON=9, DEX=11). 
§ indicates significant differences within the groups between different test days, 
tested with Wilcoxon matched-pairs signed rank test. 
* indicates significant differences between the groups on the same test day, tested 
with unpaired Students t-test with Welch’s correction 
§, *: p < 0.05, §§,**: p < 0.01, §§§, ***: p < 0.001 
Error bars represent standard error of the mean. 
ZH: Zurich, baseline; MG2: Day 2 and MG4: Day 4 at the Capanna Regina 
Margherita; 
 
 
Fig. 3 CCK and glucose metabolism, whole day 
Plasma levels of glucose (A), insulin (B) and CCK (C) in Zurich (ZH) and on Day 2 
(MG2) and Day 4 (MG4) at high altitude, measured nine times each day and 
separated retrospectively into two groups (dexamethasone-treated (DEX) and control 
group (CON)).  
*Indicates significant differences between MG4CON and MG4DEX;  
§ indicates significant differences between ZHCON and ZHDEX 
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§, *: p < 0.05, §§,**: p < 0.01, §§§, ***: p < 0.001 
Error bars represent standard error of the mean. 
ZH: Zurich, baseline; MG2: Day 2 and MG4: Day 4 at the Capanna Regina 
Margherita; 
 
Fig. 4 Glucose metabolism, fasted state 
Effects of hypoxia and dexamethasone on fasting insulin (A; n CON=9, DEX=12) in 
the first sample of each test day, insulin sensitivity by homeostasis model 
assessment (HOMA S) (B; n CON=9, DEX=12), fasting glucose to insulin ratio (G:I) 
(C; n CON=9, DEX=12) and quantitative insulin sensitivity check index (QUICKI) (D; 
n CON=9, DEX=12) 
§ indicates significant differences within the groups between different test days, 
tested with Wilcoxon matched-pairs signed rank test. 
* indicates significant differences between the groups on the same test day, tested 
with unpaired Students t-test with Welch’s correction 
§, *: p < 0.05, §§,**: p < 0.01, §§§, ***: p < 0.001 
Error bars represent standard error of the mean. 
ZH: Zurich, baseline; MG2: Day 2 and MG4: Day 4 at the Capanna Regina 
Margherita; 
 
 
 
 
Fig. 5 Food intake at ad libitum dinner (CON=9, DEX=12) 
§ indicates significant differences within the groups between different test days, 
tested with Wilcoxon matched-pairs signed rank test. 
* indicates significant differences between the groups on the same test day, tested 
with unpaired Students t-test with Welch’s correction 
§, *: p < 0.05, §§,**: p < 0.01, §§§, ***: p < 0.001 
Error bars represent standard error of the mean. 
ZH: Zurich, baseline; MG2: Day 2 and MG4: Day 4 at the Capanna Regina 
Margherita; 
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Subjects divided in dexamethasone treated group (DEX) and control group (CON); table includes age, body 
weight (BW; kg), body mass index (BMI; kg/m2), systolic (SBP; mmHg) and diastolic blood pressure (DBP; 
mmHg), erythropoietin (EPO; mU/ml), peripheral oxygen saturation (SPO2; kPa). ZH: Zurich, baseline; 
MG2: day 2 and MG4: day 4 at the Capanna Regina Margherita. 
Values are means ± SD; * indicates a significant difference to control at the same day, § indicates a 
significant difference within the same group to baseline in ZH; §,*: p<0.05, §§,**: p<0.01, §§§,***: p<0.001 
 
 
Table 1. baseline characteristics    
  
  
ZH   MG2   MG4   
CON DEX CON DEX CON DEX 
age 39.8 ±10.4 46.5 ± 8.8         
BW 72.0 ± 7.5 70.0 ± 12.1         
BMI 23.5 ± 1.1 23.9 ± 2.8         
SBP 127 ± 14 131 ± 14 132 ± 12 125 ± 12 137 ± 11 129 ± 13 
DBP 76 ± 11 80 ± 8 81 ± 7 78 ± 9 83 ± 8 80 ± 5 
EPO 7.2 ± 1.7 5.4 ± 2.0*  78.4 ± 33.8§§§ 69.0 ± 22.2§§§ 41.0 ± 17.3§§§ 23.3 ± 8.5**§§§ 
SPO2 97.2 ± 1.6 97.3 ± 1.3  78.8 ± 6.6§§§ 72.5 ± 9.1§§§ 83.4 ± 6.2§§§ 79.9 ± 7.9§§§ 
